Exploring the effectiveness and safety profile of TAU protein antibodies as potential therapies for alzheimer's disease: a comprehensive review

Abstract

Background With few effective treatments, Alzheimer's disease (AD) represents a substantial worldwide health burden. Potential disease-modifying treatments have gained attention due to recent developments in immunotherapy that target TAU protein. The purpose of this thorough analysis is to investigate the safety and efficacy of TAU protein antibodies in the treatment of AD. Methodology This review investigates the safety and efficacy of TAU protein antibodies as possible treatments for AD. Using a variety of databases, a thorough literature search was carried out with an emphasis on clinical trials and academic publications regarding TAU protein antibodies in AD. Predetermined criteria were used to select eligible studies, and pertinent data were then retrieved and compiled. PRISMA guidelines for transparency were followed in the reporting. Conclusion TAU protein antibodies have shown some potential in trials for treating Alzheimer's disease, including a little improvement in cognitive deterioration. Safety considerations highlight the need for cautious interpretation, especially with regard to imaging abnormalities due to amyloid. Optimizing efficacy, safety, and cost-effectiveness requires further studies.